• About Pharmetheus
    • History
    • Mission & Values
    • Leadership
    • Scientific advisors
    • Our team
    • Social impact (CSR)
    • Contexts of use
      • Trial design and analysis
      • Program strategies and efficiences
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientists
      • Expert Advice
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence 
& Biosimilarity
      • Accelerated submission
      • Concentration-QTc (C-QTc) modeling
      • Data-driven strategies for pediatric success
      • Training workshops
      • Publications
      • Case studies
      • Articles
    • Working with us
    • Open positions
    • Employee stories
    Qing Xi Ooi supports clients with hands-on analysis and strategic advice

    Qing Xi Ooi supports clients with hands-on analysis and strategic advice

    Viviana Moroso brings scientific depth to quality control

    Viviana Moroso brings scientific depth to quality control

    Siv Jönsson develops Pharmetheus’s learning agenda

    Siv Jönsson develops Pharmetheus’s learning agenda

  • Events
  • News
  • Contact us
  1. Home
  2. Webinars
  3. Why incorporate QSP into your oncology strategy?

Why incorporate QSP into your oncology strategy?

Address drug development bottlenecks in oncology using QSP

Webinar overview

Quantitative Systems Pharmacology (QSP) has emerged as an essential pillar of model-informed drug development (MIDD), with oncology accounting for half of all QSP-supported US FDA regulatory submissions.

By integrating preclinical biology packages and clinical data through first-principles, QSP addresses drug development bottlenecks derived from the complexity of new therapeutic hypotheses. In the context of new regulatory initiatives like the FDA’s Project Optimus and the draft guidance on QSP-based MABEL dose selection for first-in-human trials, the industry is shifting from traditional maximum tolerated dose paradigms toward rational dose optimization and clinical trial design.

This webinar highlights how QSP provides actionable frameworks that enable this transition in clinical drug development.

Sign up to secure your spot

Key topics covered

QSP helps oncology drug developers connect cellular pathways, tumor biology, and whole-body pharmacokinetics to answer questions that standard empirical models cannot.

Join our webinar to

  • Identify which type of Oncology drug development decisions QSP can address in a unique way
  • Understand how QSP can support Clinical Development teams to align with the new regulatory paradigm of Project Optimus and QSP-based MABEL dose selection for FIH
  • Gain insights from case examples across novel modalities such as T-cell engagers (TCEs), antibody–drug conjugate (ADC) combinations, and engineered T-cell therapies.

Presenters & Hosts

Principal Director, QSP Scientific Lead

Lourdes Cucurull-Sanchez

See bio

Principal Director, MIDD Scientific Lead

Martin Bergstrand

See bio

Head of Marketing & Communications

Martina Lundgren

See bio

Target audience

This webinar is designed for oncology drug developers, professionals working in pharmacometrics, translational scientists, and regulatory strategists working with complex modalities. 

Webinar details

Date: Wednesday, December 2, 2026
Time: 10:00 AM EST / 4:00 PM CET
Duration: 60 minutes (45 min presentation + 15 min live Q&A)
Cost: Free

Register your seat


Contact

Pharmetheus AB
Kungsängstull 4 

753 19 Uppsala, Sweden

Visiting address: 

Dragarbrunnsgatan 77, 5th floor

  • LinkedIn
  • YouTube
  • Science & Services
    • Contexts of use
    • Pharmetheus Platforms
    • Solutions
    • Specific services
    • Publications
    • Case studies
  • Quick links
    • About us
    • Events
    • News
    • Careers
    • Contact us
    • Newsletter

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Gasell 2017
Gasell 2020
Gasell 2021
Gasell 2022
Gasell 2023
Gasell 2024

Copyright © Pharmetheus AB 2026

  • Whistleblower
  • Privacy Policy
  • Cookie Policy